MAUDE Adverse Event Report: OLYMPUS MEDICAL SYSTEMS CORP. EVIS LUCERA DUODENOVIDEOSCOPE

Model Number JF-260V

Device Problem Adverse Event Without Identified Device or Use Problem (2993)

Patient Problems Pancreatitis (4481); Unspecified Hepatic or Biliary Problem (4493)

Event Date 11/26/2019

Event Type  Injury  

Manufacturer Narrative

The device referenced in this report has not been returned to olympus for evaluation.The investigation is ongoing.The definitive cause of the user¿s experience cannot be determined at this time.This report will be updated upon completion of the investigation or upon receipt of additional relevant.

Event Description

It is reported in the literature titled does the use of low osmolality contrast medium reduce the frequency of post-endoscopic retrograde cholangiopancreatography pancreatitis: a comparative study between use of low and high osmolality contrast media,¿ patients experienced adverse events after endoscopic retrograde cholangiopancreatography (ercp) procedures using olympus devices.Case with patient identifier (b)(6) reports pr-4q-1.Case with patient identifier (b)(6) reports kd-vc412q-0215.Case with patient identifier (b)(6) reports fg-v435p.Case with patient identifier (b)(6) reports jf-260v.Study aim: evaluate the useful ness of iodixanol for prevention pep in comparison with meglumine amidotrizoate.Method: two hundred and ninety-one patients were enrolled and divided into the 2 groups according to the contrast medium used.One hundred and fifty-five patients underwent ercp with meglumine amidotrizoate, and 136 patients underwent ercp with iodixanol.The primary outcome of this study was the incidence of pep associated with the use of each contrast medium.Results: in this study, comparison of the meglumine amidotrizoate treatment and iodixanol treatment groups showed no significant difference with respect to the incidence of pep.In addition, there was also no difference between the groups with respect to pep severity.Conclusion: this study suggested that iodixanol does not necessarily contribute to the prevention of pep in comparison with meglumine amidotrizoate.Across both study groups patients experienced post-ercp pancreatitis (pep) ranging from mild to moderate severity (there were no cases of severe pep), and post ercp hyperamylasemia.The literature does not report what treatment was required.There is no report of olympus device malfunction described in this study.

Manufacturer Narrative

This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse event cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Olympus will continue to monitor field performance for this device.

• Brand Name: EVIS LUCERA DUODENOVIDEOSCOPE
• Type of Device: DUODENOVIDEOSCOPE
• Manufacturer (Section D): OLYMPUS MEDICAL SYSTEMS CORP.; 2951 ishikawa-cho; hachioji-shi, tokyo-to 192-8 507; JA 192-8507
• Manufacturer Contact: kazutaka matsumoto ; 2951 ishikawa-cho; hachioji-shi, tokyo-to 192-8-507 ; JA 192-8507 ; 426425177
• MDR Report Key: 14102057
• MDR Text Key: 294491431
• Report Number: 8010047-2022-06190
• Device Sequence Number: 1
• Product Code: FDT
• Combination Product (y/n): N
• Reporter Country Code: JA
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Other,Foreign,Study,Literature,Health Professional
• Reporter Occupation: Physician
• Type of Report: Initial,Followup
• Report Date: 07/01/2022

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Device Operator: Health Professional
• Device Model Number: JF-260V
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Was the Report Sent to FDA?: No
• Initial Date Manufacturer Received: 03/15/2022
• Initial Date FDA Received: 04/13/2022
• Supplement Dates Manufacturer Received: 06/02/2022
• Supplement Dates FDA Received: 07/01/2022
• Was Device Evaluated by Manufacturer?: Device Not Returned to Manufacturer
• Is the Device Single Use?: No
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Reuse
• Patient Sequence Number: 1
• Patient Outcome(s): Other